Nightingale Health, (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF), a pioneer in disease risk detection and preventative health, has been selected as the multiomics provider for a large cohort study led by Aalborg University in Denmark. The total contract value is approximately EUR 2.4 million.

Led by Aalborg University, the project aims to understand the factors contributing to Inflammatory Bowel Disease and improve early detection of its onset. Nightingale Health will provide both metabolomics and proteomics analyses from the same samples. The total contract value is equivalent to 55% of the company’s revenue from the most recently published financial year.

Nightingale Health’s core service for medical research consists of affordable high-throughput analysis capturing the key functions in human metabolism. In this project, the company’s proprietary technology will also enable the selection of a sub-set of samples for additional proteomics analysis – providing a comprehensive multiomics profile from a single sample.

“This unique solution not only spares precious sample material but also reduces the overall cost of medical research by minimizing sample collection needs,” says Teemu Suna, Founder and CEO of Nightingale Health. “Our technology is the gold standard for large-scale sample analysis, and when combined with proteomics, it provides deeper insights into specific health and disease mechanisms. Being selected for this project highlights the growing demand for our integrated multiomics service – something only Nightingale can offer.”

Nightingale Health and the University of Aalborg will proceed to finalizing a service agreement after the standstill period in accordance with the public procurement process.